title: Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease.
abstract: Alzheimer's disease (AD) is characterized by progressive neurodegeneration leading to loss of cognitive abilities and ultimately to death. Postmortem investigations revealed decreased expression of cerebral insulin-like growth factor (IGF)-1 receptor (IGF-1R) and insulin receptor substrate (IRS) proteins in patients with AD. To elucidate the role of insulin/IGF-1 signaling in AD, we crossed mice expressing the Swedish mutation of amyloid precursor protein (APP(SW), Tg2576 mice) as a model for AD with mice deficient for either IRS-2, neuronal IGF-1R (nIGF-1R(-/-)), or neuronal insulin receptor (nIR(-/-)), and analyzed survival, glucose, and APP metabolism. In the present study, we show that IRS-2 deficiency in Tg2576 mice completely reverses premature mortality in Tg2576 females and delays beta-amyloid (Abeta) accumulation. Analysis of APP metabolism suggested that delayed Abeta accumulation resulted from decreased APP processing. To delineate the upstream signal responsible for IRS-2-mediated disease protection, we analyzed mice with nIGF-1R or nIR deficiency predominantly in the hippocampus. Interestingly, both male and female nIGF-1R(-/-)Tg2576 mice were protected from premature death in the presence of decreased Abeta accumulation specifically in the hippocampus formation. However, neuronal IR deletion had no influence on lethality of Tg2576 mice. Thus, impaired IGF-1/IRS-2 signaling prevents premature death and delays amyloid accumulation in a model of AD.
authors.affiliation: Department of Internal Medicine II, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
authors.forename: Susanna
authors.initials: S
authors.lastname: Freude
authors.forename: Moritz M
authors.initials: MM
authors.lastname: Hettich
authors.forename: Christina
authors.initials: C
authors.lastname: Schumann
authors.forename: Oliver
authors.initials: O
authors.lastname: Stöhr
authors.forename: Linda
authors.initials: L
authors.lastname: Koch
authors.forename: Christoph
authors.initials: C
authors.lastname: Köhler
authors.forename: Michael
authors.initials: M
authors.lastname: Udelhoven
authors.forename: Uschi
authors.initials: U
authors.lastname: Leeser
authors.forename: Marita
authors.initials: M
authors.lastname: Müller
authors.forename: Naoto
authors.initials: N
authors.lastname: Kubota
authors.forename: Takashi
authors.initials: T
authors.lastname: Kadowaki
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Krone
authors.forename: Hannsjörg
authors.initials: H
authors.lastname: Schröder
authors.forename: Jens C
authors.initials: JC
authors.lastname: Brüning
authors.forename: Markus
authors.initials: M
authors.lastname: Schubert
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D055504:Insulin Receptor Substrate Proteins / Q000235:genetics / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D008297:Male; D051379:Mice; D008817:Mice, Mutant Strains; D009474:Neurons / Q000378:metabolism*; D017526:Receptor, IGF Type 1 / Q000235:genetics / Q000378:metabolism*
chemical_list: D016229:Amyloid beta-Peptides; D055504:Insulin Receptor Substrate Proteins; C526298:Irs2 protein, mouse; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1